Cargando…

Mathematical modelling of the synergistic combination of radiotherapy and indoleamine-2,3-dioxygenase (IDO) inhibitory immunotherapy against glioblastoma

OBJECTIVE: Recent research has shown that combining radiotherapy and immunotherapy can counteract the ability of cancer to evade and suppress the native immune system. To optimise the synergy of the combined therapies, factors such as radiation dose and fractionation must be considered, alongside nu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chakwizira, Arthur, Ahlstedt, Jonatan, Nittby Redebrandt, Henrietta, Ceberg, Crister
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Institute of Radiology. 2018
Materias:	Full Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221783/ https://www.ncbi.nlm.nih.gov/pubmed/29688039 http://dx.doi.org/10.1259/bjr.20170857

Ejemplares similares

Increased effect of two-fraction radiotherapy in conjunction with IDO1 inhibition in experimental glioblastoma
por: Ahlstedt, Jonatan, et al.
Publicado: (2020)

Anti-C1-inactivator treatment of glioblastoma
por: Förnvik, Karolina, et al.
Publicado: (2018)

Long-term anti-tumor effects following both conventional radiotherapy and FLASH in fully immunocompetent animals with glioblastoma
por: Liljedahl, Emma, et al.
Publicado: (2022)

Combined anti-C1-INH and radiotherapy against glioblastoma
por: Liljedahl, Emma, et al.
Publicado: (2023)

Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus
por: Reinhart, Bonnie, et al.
Publicado: (2012)

Indoleamine 2,3‐dioxygenase (IDO)‐1 and IDO‐2 activity and severe course of COVID‐19
por: Guo, Lihui, et al.
Publicado: (2022)

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
por: Tang, Kai, et al.
Publicado: (2021)

Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing- Remitting Multiple Sclerosis
por: Mancuso, Roberta, et al.
Publicado: (2015)

Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma
por: Loeser, Heike, et al.
Publicado: (2020)

Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy
por: Yang, Pengbo, et al.
Publicado: (2023)

Single-nucleotide polymorphisms and activities of indoleamine 2,3-dioxygenase isoforms, IDO1 and IDO2, in tuberculosis patients
por: Cao, Tingming, et al.
Publicado: (2022)

Indoleamine 2,3-Dioxygenase (IDO) Downregulates the Cell Surface Expression of the CD4 Molecule
por: Huang, Guanyou, et al.
Publicado: (2012)

Indoleamine 2,3 dioxygenase (IDO) level as a marker for significant coronary artery disease
por: Wongpraparut, Nattawut, et al.
Publicado: (2021)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
por: Röhrig, Ute F., et al.
Publicado: (2022)

Indoleamine 2,3‐dioxygenase 1 (IDO1): an up‐to‐date overview of an eclectic immunoregulatory enzyme
por: Pallotta, Maria Teresa, et al.
Publicado: (2021)

Evaluating vacquinol-1 in rats carrying glioblastoma models RG2 and NS1
por: Ahlstedt, Jonatan, et al.
Publicado: (2018)

Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2
por: Lee, Young-Kwan, et al.
Publicado: (2014)

Comparable Long-Term Tumor Control for Hypofractionated FLASH Versus Conventional Radiation Therapy in an Immunocompetent Rat Glioma Model
por: Konradsson, Elise, et al.
Publicado: (2022)

Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells
por: Marttila, Saara, et al.
Publicado: (2011)

Respiratory syncytial virus replication induces Indoleamine 2,3-dioxygenase (IDO) activation in human dendritic cells
por: Ajamian, Farnam, et al.
Publicado: (2010)

Indoleamine 2,3-dioxygenase (IDO) is expressed at feto-placental unit throughout mouse gestation: An immunohistochemical study
por: Hemmati, Shayda, et al.
Publicado: (2009)

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
por: Bonanno, Giuseppina, et al.
Publicado: (2012)

Preclinical assessment of a novel small molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1)
por: Driessens, Gregory, et al.
Publicado: (2014)

Indoleamine 2,3-Dioxygenase 1 (Ido1) Is Involved in the Control of Mouse Caput Epididymis Immune Environment
por: Jrad-Lamine, Aicha, et al.
Publicado: (2013)

Immunohistochemical Features of Indoleamine 2,3-Dioxygenase (IDO) in Various Types of Lymphoma: A Single Center Experience
por: Kim, Mee-seon, et al.
Publicado: (2020)

Human Indoleamine 2,3-dioxygenase 1 (IDO1) Expressed in Plant Cells Induces Kynurenine Production
por: Bellucci, Michele, et al.
Publicado: (2021)

Fatigue in Patients on Chronic Hemodialysis: The Role of Indoleamine 2,3-Dioxygenase (IDO) Activity, Interleukin-6, and Muscularity
por: Molfino, Alessio, et al.
Publicado: (2023)

Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening
por: Sari, Suat, et al.
Publicado: (2019)

The Synergistic Local Immunosuppressive Effects of Neural Stem Cells Expressing Indoleamine 2,3-Dioxygenase (IDO) in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model
por: Lee, Young Eun, et al.
Publicado: (2015)

Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy
por: Brochez, Lieve, et al.
Publicado: (2021)

Deletion of indoleamine 2,3 dioxygenase (Ido)1 but not Ido2 exacerbates disease symptoms of MOG(35-55)-induced experimental autoimmune encephalomyelitis
por: Wetzel, Lisa A., et al.
Publicado: (2020)

Localization of Indoleamine 2,3-Dioxygenase-1 and Indoleamine 2,3-Dioxygenase-2 at the Human Maternal-Fetal Interface
por: Kudo, Yoshiki, et al.
Publicado: (2020)

Interferon-γ Regulates the Proliferation and Differentiation of Mesenchymal Stem Cells via Activation of Indoleamine 2,3 Dioxygenase (IDO)
por: Croitoru-Lamoury, Juliana, et al.
Publicado: (2011)

Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
por: Komiya, Takefumi, et al.
Publicado: (2018)

Synthesis and Molecular Modeling Studies of N′-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
por: Lee, Dong-Ho, et al.
Publicado: (2017)

Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO-1) Inhibitors Based on Ortho-Naphthaquinone-Containing Natural Product
por: Zhao, Hongchuan, et al.
Publicado: (2019)

Reliable chromatographic assay for measuring of indoleamine 2,3-dioxygenase 1 (IDO1) activity in human cancer cells
por: Sadok, Ilona, et al.
Publicado: (2021)

Increased Indoleamine 2,3-Dioxygenase 1 (IDO-1) Activity and Inflammatory Responses during Chikungunya Virus Infection
por: Alves de Souza, Thiara Manuele, et al.
Publicado: (2022)

Correction: The Synergistic Local Immunosuppressive Effects of Neural Stem Cells Expressing Indoleamine 2,3-Dioxygenase (IDO) in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model
por: Lee, Young Eun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6hvserrci3po8mrahr6bd92j7m